Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glucagon-like peptide-2 and its therapeutic use

A technology of GLP-2 and aspartic acid, applied in the direction of glucagon, hormone peptides, specific peptides, etc., can solve the problems of little understanding of the physiological role of glucagon-like peptides

Inactive Publication Date: 2008-03-12
1149336 ONTARIO
View PDF17 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In contrast to GLP-1 and other glucagon-related peptides, although multiple GLP-2 homologues have been isolated from germline animals such as humans, rats, cattle, pigs, guinea pigs, hamsters, and degus and clarified their sequence, but little is known about the physiological role of glucagon-like peptide (GLP-2)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glucagon-like peptide-2 and its therapeutic use
  • Glucagon-like peptide-2 and its therapeutic use
  • Glucagon-like peptide-2 and its therapeutic use

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0100] In the first experiment to study the effect of glucagon on the growth of the small intestine, two groups of mice (8 weeks old, CD1 female, obtained from Charles River Laboratories), 6 mice in each group, were treated as follows. Each mouse was subcutaneously injected with 0.5 cc of a 16% gelatin solution containing 41.5 µg of peptide every 12 hours for 10 consecutive days. Glucagon (rat) is easily soluble in 10ml of water. Control mice were injected with only 0.5cc of 16% gelatin solution without peptide every 12 hours. The mice were fed with standard rat chow, and the mice were given free access to food and water, and the mice were withdrawn from food and only given water 12 hours before sacrifice. For weighing the small intestine, the entire small intestine was dissected, followed by removal of the stomach (proximal) and appendix / cecum / large intestine (distal). The remaining small intestine was washed with saline to remove feces and weighed, with the following resul...

example 2

[0109] The effect of the GLP-2 peptide on the growth of the small intestine was further studied, especially to evaluate the relationship between the tissue response and the dose, time, route and frequency of administration, type of preparation, and sex and age of the subjects. The detection of these effects was reflected not only by an increase in the weight of the small intestine, but also by an increase in the height of the glandular ducts and villi.

[0110] For these purposes, rat GLP-2 was prepared as described in Example 3. This rat GLP-2 was formulated in phosphate buffered saline or as a depot formulation containing gelatin. The method of preparing GLP-2 peptide with phosphate buffered saline is as follows: first prepare 10×PBS stock solution, that is, weigh 80g NaCl (BDH ACS 783), 2g KCl (BDH ACS 645), 11.5g NaCl 2 HPO 4 (Anachemia AC-8460) and 2g KH 2 PO 4 (Malinckrodt AR7100), these reagents were dissolved in sterile distilled water in a total volume of 1 liter....

example 3

[0127] Given the results observed with rat GLP-2 in test mice, it was hypothesized that various vertebrate rat GLP-2 homologues and analogs could also mediate enterotrophic effects. For this purpose, various GLP-2 and GLP-2 analogs were synthesized and evaluated for their activity, as described below.

[0128] Solid-phase peptide synthesis (SPPS) was performed manually in 300 milliliter (ml) vessels at the 3 millimole (mmole) scale using 6 grams (g) of chloromethyl (Merrifield) resin (for C-terminal free acid peptide), 0.5 milliequivalents (meq) per gram of substitution. Amino acids are protected at the amino terminus with a tert-butoxycarbonyl (tBoc) group. Amino acid side chains are protected using benzyl (Bz, for serine and threonine), benzyloxymethyl (BOM, for histidine), 2-bromobenzyloxycarbonyl (2-BrZ, for tyrosine ), 2-chlorobenzyloxycarbonyl (2-ClZ, for lysine), cyclohexyl (cHex, for aspartic acid and glutamic acid), and tosylate (Ts, for arginine ) side chain prote...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Glucagon-like peptide-2, a product of glucagon gene expression, and analogs of glucagon-like peptide-2, have been identified as gastrointestinal tissue growth factors. Their effects on the growth of small bowel and pancreatic islets are described. Their formulation as a pharmaceutical, and their therapeutic use in treating disorders of the bowel, are described.

Description

[0001] Cross-references with related applications [0002] This application is a partial continuation of the application (serial number: 08 / 422,540) filed on April 14, 1995, and the content of the original application is incorporated here for reference. field of invention [0003] The present invention relates to glucagon-related peptides which have growth-promoting properties of gastrointestinal tissue. The invention also relates to the therapeutic use of these peptides for the treatment of various diseases caused by poor growth or loss of gastrointestinal tissue, especially intestinal and pancreatic tissue. Background of the invention [0004] Expression of the glucagon gene produces tissue-specifically diverse peptide products derived from the processing of the 160-residue proglucagon product. since Preproglucagon cDNA was prepared from pancreas of pig, rat, hamster and bovine, and its molecular cloning was carried out, and the structural composition of these peptides ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/605A61K38/26A61K38/00A61P1/00A61P1/04A61P1/18A61P3/08
CPCG01N33/74C07K14/605G01N2500/00A61K38/00G01N2333/605A61P1/00A61P1/04A61P1/14A61P1/18A61P29/00A61P3/10A61P3/08A61P43/00
Inventor D·J·德鲁克尔
Owner 1149336 ONTARIO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com